MOMS (Management of Myelomeningocele Study) was a research study designed to compare two approaches to the treatment of babies with spina bifida: surgery before birth (prenatal or fetal surgery) and surgery after birth (postnatal surgery).
MOMS2 (Management of Myelomeningocele Study) was the continuation of The Management of Myelomeningocele Study, a school-age follow-up assessment of prenatal versus postnatal repair of myelomeningocele conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) with co-funding from the National Institute of Neurological Disorders and Stroke (NINDS)

MOMS began in 2003 and MOMS2 ended in 2017.  Links to the published results appear below.

• A randomized trial of prenatal versus postnatal repair of myelomeningocele
  DOI: 10.1056/NEJMoa1014379 PMCID: PMC3770179
• The Management of Myelomeningocele Study: full cohort 30-month pediatric outcomes
  DOI: 10.1016/j.ajog.2017.12.001 PMCID: PMC7737375 
• Prenatal Repair of Myelomeningocele and School-age Functional Outcomes
  DOI: 10.1542/peds.2019-1544 PMCID: PMC6993457 

Clinicaltrials.gov:   NCT00060606